Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.
Key persons should be involved in policy for pandemics RIVM advises government authorities to involve ‘key persons’ in formulating policy for current and future pandemics. Results from RIVM research show that these individuals played a key role in ensuring an ongoing focus on social well-being and mental health during the COVID-19 pandemic, despite the limitations.
National Immunisation Programme: new decline in number of reported cases of disease in 2021 In 2021, fewer people contracted diseases for which vaccines are offered under the National Immunisation Programme (NIP) than before the coronavirus pandemic. This is very likely largely due to the impact of the coronavirus measures, such as social distancing and hand washing.
Patient with cutaneous diphtheria in reception centre This week, a refugee from Syria was found to be infected with the diphtheria bacterium. The patient has been treated with antibiotics. The patient’s contacts have been tested and vaccinated.
Almost half of 9 and 10-year-olds get HPV vaccination at first opportunity This spring, more than 800,000 young people received an invitation to be vaccinated against HPV, the human papillomavirus.
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
Public opinion: keep society open and continue providing healthcare during COVID-19 surge In the long-term approach to the COVID-19 pandemic, the Dutch government is assigning a key role to civil society and private citizens. When asked what their priorities are in that context, the answer was to prevent delays in surgical interventions.